|
|
Advances and Applications of Recombinant Antibody Drugs |
ZHANG Ying1, HE Jin-Sheng1, HONG Chao1,2 |
1.College of Life Sciences and Bioengineering, School of Science, Beijing Jiaotong University, Beijing100044,China
2.Institute for Viral Disease Control and Prevention, China CDC, Beijing100052,China |
|
|
Abstract Recombinant antibody drugs has developed through mice monoclonal antibody(McAb), humanmice chimeric antibody, humanized antibody and full human antibody. They have been applied in clinical immunotherapy for the treatment of cancer, autoimmune diseases, viral diseases and Alzheimer disease, etc. The two basic principles in antibody humanization are keeping or enhancing affinity and reducing immunogenicity of engineered antibodies. The degree of humanization has approached 100% following the continuously improved techniques, such as CDR grafting, resurfacing, antibody library and transgenic mice. However, the gap between the basic research and clinical application still need to be filled. The outline, challenge and perspective in application associated to recombinant antibody drugs were reviewed here.
|
Received: 15 April 2009
Published: 28 July 2009
|
|
Corresponding Authors:
Ying Zhang
|
|
|
[1] Morrison S L, Johnson M J, Herzenberg L A, et al. Chimeric human antibody molecules: Mouse antigenbinding domains with human constant region domains. Proc Natl Acad Sci USA, 1984, 81: 6851~6855
[2] 沈倍奋,陈志南,刘民培. 重组抗体. 北京:科学出版社,2005.217~234
Shen B F, Chen Z N, Liu M P. Beijing: Science Press,2005.217~234
[3] 沈倍奋. 抗体药物研究进展. 第二军医大学学报, 2002, 23 (10): 1047~1049
Shen B F. Acad J Sec Mil Med Univ, 2002, 23 (10): 1047~1049
[4] Booy E P, Johar D, Maddika S,et al. Monoclonal and bispecific antibodies as novel therapeutics.
[5] 陈志南. 基于抗体的中国生物制药产业化前景. 中国医药生物技术, 2007, 2 (1): 2~5
Chen Z N. Chin Med Biotechol, 2007, 2 (1): 2~5
[6] Hwang W Y, Foote J. Immunogenicity of engineered antibodies. Methods, 2005, 36 (1):3~10
[7] Kashmiri S V, De Pascalis R, Gonzales N R, et al. SDR grafting——a new approach to antibody humanization. Methods, 2005, 36 (1):25~34
[8] Clark M. Antibody humanization: a case of the ‘Emperor’s new clothes’? Immunol Today, 2000, 21 (8):397~402
[9] Leonard J P, Coleman M, Ketas J C, et al. Epratuzumab, a humanized antiCD22 antibody, in aggressive nonHodgkin’s lymphoma. Clin Cancer Res, 2004, 10 (16): 5327~5334
[10] 中国首个基因重组人源化单克隆抗体药物上市. 中国医药生物技术. 2008, 3 (5): 384
Chin Med Biotechol, 2008, 3 (5): 384
[11] Haymes L M, Tonkin J, Anderson L J, et al. Neutralizing antiF glycoprotein and antisubstance Pantibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol, 2002, 76 (14): 6873~6881
[12] Lambert M P, Barlow A K, Chromy B A, et al. Diffusible, nonfibrillar ligands derived from Abeta142 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A, 1998, 95 (11):6448~6453
[13] Bard F, Cannon C, Barbour R, et al.Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med, 2000, 6 (8):916~919
[14] Lee E B, Leng L Z, Zhang B, et al. Targeting amyloidbeta peptide (Aβ) oligomers by passive immunization with a conformationselective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem, 2006, 281 (7):4292~4299
[15] Hawkes C A, McLaurin J. Clinical immunotherapy trials in Alzheimer’s disease. Drug Discovery Today: Therapeutic Strategies, 2008(in press)
[16] Wilcock D M, Colton C A. Antiamyloidbeta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis, 2008, 15 (4):555~569
[17] Thakker D R, Weatherspoon M R, Harrison J, et al. Intracerebroventricular amyloid{beta} antibodies reduce cerebral amyloid angiopathy and associated microhemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A, 2009, 25(in press)
[18] Weinblatt M E, Keystone E C, Furst D E, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheumatic Dis, 2006, 65 (6): 753~759 |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|